Anthera Pharmaceuticals Inc (ANTH) Expected to Post Earnings of -$0.53 Per Share

Equities analysts expect Anthera Pharmaceuticals Inc (NASDAQ:ANTH) to post ($0.53) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Anthera Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.46). Anthera Pharmaceuticals reported earnings per share of ($0.86) during the same quarter last year, which suggests a positive year-over-year growth rate of 38.4%. The company is scheduled to report its next quarterly earnings report on Wednesday, August 8th.

According to Zacks, analysts expect that Anthera Pharmaceuticals will report full year earnings of ($2.28) per share for the current year, with EPS estimates ranging from ($2.37) to ($2.19). For the next year, analysts anticipate that the company will post earnings of ($1.78) per share, with EPS estimates ranging from ($2.02) to ($1.54). Zacks’ EPS calculations are an average based on a survey of research firms that cover Anthera Pharmaceuticals.

Several equities research analysts have weighed in on ANTH shares. Zacks Investment Research cut shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, February 21st. Jefferies Financial Group restated a “hold” rating and issued a $0.50 price objective on shares of Anthera Pharmaceuticals in a research report on Thursday, March 15th. Roth Capital started coverage on shares of Anthera Pharmaceuticals in a research report on Wednesday, February 21st. They issued a “buy” rating and a $10.00 price objective for the company. ValuEngine upgraded shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Finally, Piper Jaffray Companies cut shares of Anthera Pharmaceuticals from an “overweight” rating to an “underweight” rating in a research report on Monday, March 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $3.44.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Armistice Capital LLC acquired a new stake in shares of Anthera Pharmaceuticals during the 4th quarter worth approximately $1,269,000. BVF Inc. IL grew its position in shares of Anthera Pharmaceuticals by 20.9% during the 4th quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock worth $2,007,000 after buying an additional 209,896 shares during the period. Finally, 683 Capital Management LLC acquired a new stake in shares of Anthera Pharmaceuticals during the 4th quarter worth approximately $399,000. Hedge funds and other institutional investors own 7.49% of the company’s stock.

ANTH traded down $0.01 during midday trading on Friday, hitting $0.31. The company had a trading volume of 658,100 shares, compared to its average volume of 1,994,474. The stock has a market capitalization of $7.62 million, a PE ratio of -0.08 and a beta of 2.69. Anthera Pharmaceuticals has a twelve month low of $0.21 and a twelve month high of $2.97.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.

Get a free copy of the Zacks research report on Anthera Pharmaceuticals (ANTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply